Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of rheumatoid arthritis (RA) according to EULAR/ACR 2010 classification criteria * DAS28 ≤ 5.1 * Current maintenance treatment with Rituximab regardless of dose and/or duration of Rituximab treatment and with at least first cycle of Rituximab ended (2 initial infusions) * Last Rituximab infusion between 6 and 18 months prior to inclusion * Corticosteroids ≤10 mg/day within 4 weeks prior to inclusion * Affiliation to a social insurance system or beneficiary * Written informed consent to participate in the study, dated and signed before starting the trial * Effective method of birth control during the study Exclusion Criteria: * Rheumatic autoimmune disease other than RA (except associated Sjogren's disease, which is allowed) * Concurrent treatment with any other targeted therapy than Rituximab * Any contraindication to Rituximab or to NaCl 0.9% * Significant uncontrolled associated disease or comorbidity * Known active infection or history of serious recurrent or chronic infection * Laboratory findings: active or untreated latent tuberculosis, hepatitis B positive, hepatitis C positive, haemoglobin \<8 g/dL, neutropenia \< 1.5G/L, IgM \<0.4 g/L and/or IgG \<5 g/L * Pregnancy, breastfeeding, or planned pregnancy during the study (on subject declaration) * Drug addiction, alcohol addiction * Patients who cannot be followed for the 12 month-duration * Patients over the age of legal majority who are protected, or deprived of liberty by judicial or administrative decision * Subject in exclusion period (determined by a previous or ongoing study) * Patients unable to give informed consent (e.g., patients in a situation of medical emergency, patients who have difficulty comprehending the essential details of the trial...) * Patients who have difficulty reading or understanding French, or who have an inability to understand the delivered information